

Robert Bristow

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6488764/robert-bristow-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

242
papers

14,264
citations

67
h-index

112
g-index

265
ext. papers

17,104
ext. citations

8.1
avg, IF

6.28
L-index

#	Paper	IF	Citations
242	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 , 40, 5.e1-5.e13	2.8	
241	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , 2022 ,	10.2	2
240	The telomere length landscape of prostate cancer. <i>Nature Communications</i> , 2021 , 12, 6893	17.4	0
239	Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors. <i>Cancer Research</i> , 2021 , 81, 5833-5848	10.1	2
238	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. <i>Nature Communications</i> , 2021 , 12, 6248	17.4	3
237	Lost in application: Measuring hypoxia for radiotherapy optimisation. <i>European Journal of Cancer</i> , 2021 , 148, 260-276	7.5	9
236	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. <i>BMC Urology</i> , 2021 , 21, 96	2.2	1
235	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 9	51.1	72
234	Prostate cancer. <i>Lancet, The</i> , 2021 , 398, 1075-1090	40	28
233	[F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. <i>BMJ Open</i> , 2020 , 10, e035959	3	3
232	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
231	Divergent mutational processes distinguish hypoxic and normoxic tumours. <i>Nature Communications</i> , 2020 , 11, 737	17.4	46
230	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. <i>Nature Communications</i> , 2020 , 11, 441	17.4	21
229	The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. <i>Lancet Oncology, The</i> , 2020 , 21, 17-19	21.7	8
228	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. <i>Molecular Cell</i> , 2020 , 80, 562-577	17.6	12
227	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2020 ,	6.7	6
226	Sex differences in oncogenic mutational processes. <i>Nature Communications</i> , 2020 , 11, 4330	17.4	23

225	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. <i>NAR Cancer</i> , 2020 , 2, zcaa012	5.2	1
224	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. <i>PLoS Medicine</i> , 2020 , 17, e1003281	11.6	8
223	Bad neighbours: hypoxia and genomic instability in prostate cancer. <i>British Journal of Radiology</i> , 2020 , 93, 20200087	3.4	7
222	Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 247-255	9.7	13
221	The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report. <i>European Journal of Cancer</i> , 2020 , 131, 76-88	7.5	8
220	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , 2019 , 25, 1615-1626	50.5	25
219	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019 , 10, 278	17.4	72
218	Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3818-3829	12.9	26
217	The Proteogenomic Landscape of Curable Prostate Cancer. <i>Cancer Cell</i> , 2019 , 35, 414-427.e6	24.3	97
216	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 61-66	4	3
215	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019 , 176, 831-843.e23	36.2	214
214	The influence of BRCA2 mutation on localized prostate cancer. <i>Nature Reviews Urology</i> , 2019 , 16, 281-295	9.5	36
213	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. <i>Cancer Cell</i> , 2019 , 36, 674-689.e6	24.3	21
212	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 84-91	4	20
211	and Prognosis in mCRPC Survival: Biology or Coincidence?. <i>Clinical Cancer Research</i> , 2019 , 25, 1699-1701	12.9	3
210	Molecular landmarks of tumor hypoxia across cancer types. <i>Nature Genetics</i> , 2019 , 51, 308-318	36.3	255
209	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 38-45	3.3	18
208	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , 2018 , 19, e240-e251	21.7	66

207	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018 , 50, 682-692	36.3	112
206	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. <i>Cell</i> , 2018 , 173, 1003-1013.e15	56.2	115
205	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 702-709	4	1
204	NanoStringNormCNV: pre-processing of NanoString CNV data. <i>Bioinformatics</i> , 2018 , 34, 1034-1036	7.2	2
203	The Future of Radiobiology. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 329-340	9.7	46
202	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018 , 31, 182-189	8.8	67
201	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. <i>BMC Cancer</i> , 2018 , 18, 8	4.8	54
200	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. <i>Cancer Cell</i> , 2018 , 34, 996-1011.e8	24.3	89
199	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. <i>BMC Urology</i> , 2018 , 18, 78	2.2	6
198	Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma. <i>PLoS ONE</i> , 2018 , 13, e0194809	3.7	9
197	Valection: design optimization for validation and verification studies. <i>BMC Bioinformatics</i> , 2018 , 19, 339	3.6	1
196	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. <i>Clinical Cancer Research</i> , 2018 , 24, 3500-3509	12.9	2
195	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017 , 541, 359-364	50.4	320
194	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. <i>Nature Communications</i> , 2017 , 8, 13671	17.4	128
193	Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. <i>Radiation Research</i> , 2017 , 187, 147-160	3.1	33
192	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. <i>Oncologist</i> , 2017 , 22, 152-157	5.7	5
191	Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2017 , 124, 427-432	5.3	8
190	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017 , 123, 459-465	5.3	10

189	A Prostate Cancer "Nimbusus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017 , 72, 665-674	10.2	98
188	Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. <i>Current Problems in Cancer</i> , 2017 , 41, 265-272	2.3	9
187	Comparison of pre-processing methods for Infinium HumanMethylation450 BeadChip array. <i>Bioinformatics</i> , 2017 , 33, 3151-3157	7.2	7
186	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	12
185	Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. <i>Oncotarget</i> , 2017 , 8, 4668-4689	3.3	58
184	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2299-2305	2.2	153
183	Mitochondrial mutations drive prostate cancer aggression. <i>Nature Communications</i> , 2017 , 8, 656	17.4	66
182	Loss of p27 increases genomic instability and induces radio-resistance in luminal breast cancer cells. <i>Scientific Reports</i> , 2017 , 7, 595	4.9	16
181	TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. <i>Nature Genetics</i> , 2017 , 49, 1336-1345	36.3	105
180	Radiosensitization by gold nanoparticles: Will they ever make it to the clinic?. <i>Radiotherapy and Oncology</i> , 2017 , 124, 344-356	5.3	93
179	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. <i>Radiation Oncology</i> , 2017 , 12, 50	4.2	4
178	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017 , 72, 22-31	10.2	28
177	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2017 , 122, 93-98	5.3	17
176	Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. <i>Oncotarget</i> , 2017 , 8, 87638-87646	3.3	7
175	The Clinical Genomics of Prostate Cancer 2017 , 97-110		1
174	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. <i>Nature Genetics</i> , 2016 , 48, 1142-50	36.3	158
173	Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer. <i>Radiation Research</i> , 2016 , 185, 549-62	3.1	21
172	BAMQL: a query language for extracting reads from BAM files. <i>BMC Bioinformatics</i> , 2016 , 17, 305	3.6	11

171	PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer. <i>Cancer</i> , 2016 , 122, 2595-603	6.4	6
170	Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors. <i>Neoplasia</i> , 2016 , 18, 347-55	6.4	56
169	Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy. <i>Prostate</i> , 2016 , 76, 1169-81	4.2	21
168	Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. <i>Journal of Clinical Oncology</i> , 2016 , 34, e80-3	2.2	1
167	In Vitro and In Vivo Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 640-50	6.1	10
166	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016 , 7, 57726-57736	3.3	40
165	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. <i>Canadian Urological Association Journal</i> , 2016 , 10, 25-30	1.2	15
164	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2016 , 6, 24	5.3	17
163	MATE2 Expression Is Associated with Cancer Cell Response to Metformin. <i>PLoS ONE</i> , 2016 , 11, e0165214	3.7	21
162	Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. <i>PLoS ONE</i> , 2016 , 11, e0167272	3.7	18
161	Clonality of localized and metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2016 , 26, 219-24	2.8	7
160	Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?. <i>Clinical Cancer Research</i> , 2016 , 22, 3124-6	12.9	13
159	Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality. <i>Cancer Drug Discovery and Development</i> , 2015 , 345-361	0.3	
158	Hypoxia and Predicting Radiation Response. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 260-72	5.5	54
157	Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells. <i>Radiotherapy and Oncology</i> , 2015 , 116, 388-91	5.3	6
156	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. <i>Nature Genetics</i> , 2015 , 47, 367-372	36.3	292
155	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. <i>Nature Reviews Urology</i> , 2015 , 12, 193-204	5.5	30
154	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. <i>Practical Radiation Oncology</i> , 2015 , 5, e473-e482	2.8	17

153	In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. <i>Radiotherapy and Oncology</i> , 2015 , 116, 486-94	5.3	39
152	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 85-94	2.8	89
151	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. <i>Prostate</i> , 2015 , 75, 1277-84	4.2	40
150	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015 , 47, 736-45	36.3	306
149	MR-guided prostate biopsy for planning of focal salvage after radiation therapy. <i>Radiology</i> , 2015 , 274, 181-91	20.5	34
148	Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. <i>PLoS ONE</i> , 2015 , 10, e0121872	3.7	17
147	Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. <i>Oncotarget</i> , 2015 , 6, 1900-19	3.3	65
146	Prostate Cancer Genomics as a Driver of Personalized Medicine 2014 , 233-245		1
145	Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 11-7	4	15
144	DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. <i>Molecular Cell</i> , 2014 , 53, 7-18	17.6	371
143	SeqControl: process control for DNA sequencing. <i>Nature Methods</i> , 2014 , 11, 1071-5	21.6	6
142	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 195-204	3.5	21
141	ShatterProof: operational detection and quantification of chromothripsis. <i>BMC Bioinformatics</i> , 2014 , 15, 78	3.6	42
140	Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. <i>Molecular Pharmaceutics</i> , 2014 , 11, 2659-74	5.6	47
139	Deriving patient-specific planning target volume for partial bladder image guided radiation therapy. <i>Practical Radiation Oncology</i> , 2014 , 4, 323-329	2.8	5
138	Linking the history of radiation biology to the hallmarks of cancer. <i>Radiation Research</i> , 2014 , 181, 561-773.1		31
137	Use of Sequenom sample ID Plus SNP genotyping in identification of FFPE tumor samples. <i>PLoS ONE</i> , 2014 , 9, e88163	3.7	12
136	Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. <i>Canadian Urological Association Journal</i> , 2014 , 8, E783-8	1.2	6

135	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology, The</i> , 2014 , 15, 1521-1532	21.7	218
134	Hypoxia and cellular localization influence the radiosensitizing effect of gold nanoparticles (AuNPs) in breast cancer cells. <i>Radiation Research</i> , 2014 , 182, 475-88	3.1	45
133	High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. <i>International Journal of Cancer</i> , 2014 , 135, 1692-9	7.5	23
132	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014 , 2, 174	7.3	32
131	Hypoxia provokes base excision repair changes and a repair-deficient, mutator phenotype in colorectal cancer cells. <i>Molecular Cancer Research</i> , 2014 , 12, 1407-15	6.6	39
130	Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. In regard to Freedland et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 237-40	4	4
129	RNF8-independent Lys63 poly-ubiquitylation prevents genomic instability in response to replication-associated DNA damage. <i>PLoS ONE</i> , 2014 , 9, e89997	3.7	1
128	NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. <i>Oncotarget</i> , 2014 , 5, 11081-90	3.3	25
127	Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 772, 189-204	3.6	26
126	In reply to Nieder. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 581	4	
125	Imatinib radiosensitizes bladder cancer by targeting homologous recombination. <i>Cancer Research</i> , 2013 , 73, 1611-20	10.1	29
124	Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. <i>ACS Nano</i> , 2013 , 7, 4221-32	16.7	85
123	Neoplastic cell response to tiopronin-coated gold nanoparticles. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013 , 9, 264-73	6	13
122	Investigations of antioxidant-mediated protection and mitigation of radiation-induced DNA damage and lipid peroxidation in murine skin. <i>International Journal of Radiation Biology</i> , 2013 , 89, 618-27	2.9	20
121	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. <i>Canadian Urological Association Journal</i> , 2013 , 5, 31	1.2	
120	4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2013 , 61, 500-9	3.4	5
119	miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. <i>Cancer Research</i> , 2013 , 73, 6972-86	10.1	111
118	Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. <i>Laboratory Investigation</i> , 2013 , 93, 397-407	5.9	22

117	Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. <i>Journal of Molecular Cell Biology</i> , 2013 , 5, 428-31	6.3	15
116	Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. <i>Clinical Cancer Research</i> , 2013 , 19, 6741-50	12.9	213
115	TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. <i>Clinical Cancer Research</i> , 2013 , 19, 5202-9	12.9	34
114	Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2013 , 37, 909-16	5.6	60
113	Tumor hypoxia as a driving force in genetic instability. <i>Genome Integrity</i> , 2013 , 4, 5	0.8	140
112	Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis. <i>PLoS ONE</i> , 2013 , 8, e82363	3.7	17
111	Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. <i>Cell Cycle</i> , 2012 , 11, 1432-44	4.7	40
110	Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, e441-8	4	44
109	Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 608-16	4	9
108	Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to "Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721-727). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, e507-14	4	3
107	AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, e507-14	4	39
106	Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. <i>Radiotherapy and Oncology</i> , 2012 , 102, 459-65	5.3	33
105	Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. <i>Prostate</i> , 2012 , 72, 1295-305	4.2	10
104	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. <i>Journal of Pathology</i> , 2012 , 227, 53-61	9.4	51
103	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. <i>Journal of Pathology</i> , 2012 , 227, 286-97	9.4	142
102	Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. <i>Cancer</i> , 2012 , 118, 4053-62	6.4	90
101	Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 10175-80	11.5	29
100	PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. <i>Clinical Cancer Research</i> , 2012 , 18, 1015-27	12.9	100

99	Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 2108-14	12.9	181
98	NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. <i>Clinical Cancer Research</i> , 2012 , 18, 308-16	12.9	38
97	Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. <i>Journal of Cell Science</i> , 2012 , 125, 189-99	5.3	90
96	Association between germline HOXB13 G84E mutation and risk of prostate cancer. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1260-2	9.7	56
95	Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4025-36	15.9	33
94	Biodosimetry using radiation-induced micronuclei in skin fibroblasts. <i>International Journal of Radiation Biology</i> , 2011 , 87, 824-38	2.9	8
93	Direct observation of ultrafast-electron-transfer reactions unravels high effectiveness of reductive DNA damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 11778-83	11.5	89
92	Protein-protein interactions occur between p53 phosphoforms and ATM and 53BP1 at sites of exogenous DNA damage. <i>Radiation Research</i> , 2011 , 175, 588-98	3.1	13
91	A role for p53 in the response of bystander cells to receipt of medium borne signals from irradiated cells. <i>International Journal of Radiation Biology</i> , 2011 , 87, 1120-5	2.9	46
90	Patient-specific PTV margins in radiotherapy for bladder cancer - a feasibility study using cone beam CT. <i>Radiotherapy and Oncology</i> , 2011 , 99, 131-6	5.3	24
89	ATM-dependent phosphorylation of 53BP1 in response to genomic stress in oxic and hypoxic cells. <i>Radiotherapy and Oncology</i> , 2011 , 99, 307-12	5.3	17
88	Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. <i>Radiotherapy and Oncology</i> , 2011 , 101, 190-7	5.3	32
87	The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. <i>Radiotherapy and Oncology</i> , 2011 , 101, 59-65	5.3	28
86	Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, e415-21	4	23
85	Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. <i>Radiation Oncology</i> , 2011 , 6, 144	4.2	58
84	Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities Report of an NCI Workshop held September 1B, 2010. <i>Radiation Research</i> , 2011 , 176, e0016-e0021	3.1	3
83	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 107-13	19.4	23
82	In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2130-2	2.2	2

81	MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. <i>Cell Cycle</i> , 2011 , 10, 2218-32	4.7	99
80	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. <i>Canadian Urological Association Journal</i> , 2011 , 5, E31-5	1.2	12
79	Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. <i>Cancer Research</i> , 2010 , 70, 8748-59	10.1	62
78	Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. <i>Journal of Experimental Medicine</i> , 2010 , 207, 983-97	16.6	97
77	MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. <i>Cancer Research</i> , 2010 , 70, 7017-26	10.1	148
76	Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. <i>Cancer Research</i> , 2010 , 70, 8045-54	10.1	176
75	"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. <i>Clinical Cancer Research</i> , 2010 , 16, 4553-60	12.9	91
74	Gold nanoparticles as radiation sensitizers in cancer therapy. <i>Radiation Research</i> , 2010 , 173, 719-28	3.1	436
73	Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. <i>Radiation Research</i> , 2010 , 173, 1-9	3.1	54
72	The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination. <i>Molecular Cell</i> , 2010 , 40, 619-31	17.6	85
71	Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. <i>Acta Oncologica</i> , 2010 , 49, 888-94	3.2	28
70	Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. <i>Seminars in Radiation Oncology</i> , 2010 , 20, 274-81	5.5	104
69	DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. <i>Seminars in Radiation Oncology</i> , 2010 , 20, 217-22	5.5	57
68	A cinematic magnetic resonance imaging study of milk of magnesia laxative and an antifatulent diet to reduce intrafraction prostate motion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 1072-8	4	45
67	Response to "Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects" (Int J Radiat Oncol Biol Phys 2009; in press). <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 1277; author reply 1277	4	1
66	Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 221-9	4	161
65	Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. <i>Journal of Cell Biology</i> , 2010 , 189, i6-i6	7.3	
64	Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 203-13	6.1	87

63	Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. <i>Clinical Cancer Research</i> , 2009 , 15, 5576-83	12.9	41
62	High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. <i>Prostate</i> , 2009 , 69, 1091-100	4.2	71
61	Image guided dose escalated prostate radiotherapy: still room to improve. <i>Radiation Oncology</i> , 2009 , 4, 50	4.2	48
60	Correction: Image guided dose escalated prostate radiotherapy: still room to improve. <i>Radiation Oncology</i> , 2009 , 4, 65	4.2	1
59	Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. <i>International Journal of Radiation Biology</i> , 2009 , 85, 805-13	2.9	88
58	Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. <i>Gastroenterology</i> , 2009 , 136, 1251-60	13.3	165
57	Microscopic imaging of DNA repair foci in irradiated normal tissues. <i>International Journal of Radiation Biology</i> , 2009 , 85, 732-46	2.9	45
56	IMRT and molecular biological approaches in radiotherapy for prostate cancer. <i>European Journal of Cancer</i> , 2009 , 45 Suppl 1, 429-30	7.5	1
55	Tumor hypoxia as a modifier of DNA strand break and cross-link repair. <i>Current Molecular Medicine</i> , 2009 , 9, 401-10	2.5	28
54	Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. <i>Nature Reviews Cancer</i> , 2008 , 8, 180-92	31.3	827
53	Characterization of mutant MUTYH proteins associated with familial colorectal cancer. <i>Gastroenterology</i> , 2008 , 135, 499-507	13.3	80
52	PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTP53-status. <i>Radiotherapy and Oncology</i> , 2008 , 86, 407-11	5.3	32
51	A randomized comparison of interfraction and intrafraction prostate motion with and without abdominal compression. <i>Radiotherapy and Oncology</i> , 2008 , 88, 88-94	5.3	23
50	A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. <i>Radiotherapy and Oncology</i> , 2008 , 88, 53-60	5.3	24
49	A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. <i>Radiotherapy and Oncology</i> , 2008 , 88, 258-68	5.3	114
48	Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. <i>Cancer Research</i> , 2008 , 68, 605-14	10.1	244
47	Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 993-9	6.1	56
46	WTp53 induction does not override MTP53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 980-92	6.1	13

45	Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells. <i>Plastic and Reconstructive Surgery</i> , 2008 , 122, 1025-1035	2.7	15
44	Biomarkers of clinical trials using molecular inhibitors and radiotherapy: state-of-the-art. Preface. <i>Cancer and Metastasis Reviews</i> , 2008 , 27, 337-8	9.6	2
43	Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. <i>Cancer and Metastasis Reviews</i> , 2008 , 27, 445-58	9.6	31
42	Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. <i>Cancer and Metastasis Reviews</i> , 2008 , 27, 375-85	9.6	12
41	Analysis of variants in DNA damage signalling genes in bladder cancer. <i>BMC Medical Genetics</i> , 2008 , 9, 69	2.1	34
40	Overview of Cancer Molecular Radiobiology. <i>Cancer Treatment and Research</i> , 2008 , 115-131	3.5	1
39	Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. <i>Future Oncology</i> , 2007 , 3, 329-41	3.6	67
38	Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 1084-9	4	119
37	Novel chemical enhancers of heat shock increase thermal radiosensitization through a mitotic catastrophe pathway. <i>Cancer Research</i> , 2007 , 67, 695-701	10.1	32
36	Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. <i>Cancer Research</i> , 2007 , 67, 6022-5	10.1	96
35	Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 303-9	2.8	76
34	Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. <i>Radiotherapy and Oncology</i> , 2007 , 83, 220-30	5.3	53
33	Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. <i>Seminars in Radiation Oncology</i> , 2006 , 16, 51-8	5.5	87
32	Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. <i>Journal of Cell Biology</i> , 2006 , 175, 55-66	7.3	135
31	Treatment of radiation proctitis with hyperbaric oxygen. <i>Radiotherapy and Oncology</i> , 2006 , 78, 91-4	5.3	50
30	A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2006 , 5, 235-7	3.3	2
29	Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy. <i>Canadian Journal of Urology</i> , 2006 , 13 Suppl 2, 63-7	0.8	1
28	Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. <i>Cancer</i> , 2005 , 104, 891-905	6.4	49

27	Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. <i>Radiotherapy and Oncology</i> , 2005 , 76, 168-76	5.3	156
26	Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1059, 184-95	6.5	61
25	Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells using Comet-FISH. <i>Breast Cancer Research and Treatment</i> , 2005 , 91, 89-93	4.4	30
24	Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. <i>Prostate</i> , 2005 , 65, 124-9	4.2	22
23	Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. <i>Cancer Research</i> , 2005 , 65, 11597-604	10.1	269
22	Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. <i>Cancer Research</i> , 2005 , 65, 10810-21	10.1	90
21	Basis of Cell Kill Following Clinical Radiotherapy 2005 , 293-320		6
20	Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. <i>Cancer Research</i> , 2004 , 64, 8526-33	10.1	99
19	The p53 protein family and radiation sensitivity: Yes or no?. <i>Cancer and Metastasis Reviews</i> , 2004 , 23, 237-57	9.6	100
18	Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. <i>Molecular and Cellular Biology</i> , 2004 , 24, 8504-18	4.8	291
17	A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2004 , 70, 37-44	5.3	83
16	Recommendations for the future of translational radiobiology research: a Canadian perspective. <i>Radiotherapy and Oncology</i> , 2004 , 70, 159-64	5.3	7
15	Re: Vikram, B., The PSA conundrum. [Radiother Oncol, 2004. 71(1): p. 1-2]. <i>Radiotherapy and Oncology</i> , 2004 , 73, 252-4; author reply 254-5	5.3	1
14	Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2760-76	2.2	115
13	Comment on "Tumor response to radiotherapy regulated by endothelial cell apoptosis" (II). <i>Science</i> , 2003 , 302, 1894; author reply 1894	33.3	35
12	Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTP53. <i>Oncogene</i> , 2003 , 22, 2960-6	9.2	20
11	Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management. <i>Urologic Clinics of North America</i> , 2003 , 30, 751-63	2.9	22
10	Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003. <i>Radiation Research</i> , 2003 , 160, 729-37	3.1	22

9	Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. <i>Molecular and Cellular Biology</i> , 2002 , 22, 6521-32	4.8	316
8	Expression of different mutant p53 transgenes in neuroblastoma cells leads to different cellular responses to genotoxic agents. <i>Experimental Cell Research</i> , 2002 , 275, 122-31	4.2	17
7	Radioresistant MTP53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation. <i>Oncogene</i> , 1998 , 16, 1789-802	9.2	37
6	T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 41, 347-53	4	150
5	The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. <i>Radiotherapy and Oncology</i> , 1996 , 40, 197-223	5.3	163
4	P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996 , 34, 341-55	4	10
3	p53 protein expression or protein function?. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996 , 35, 1123-5	4	2
2	Biology of Cancer3-22		
1	Candidate cancer driver mutations in superenhancers and long-range chromatin interaction networks		5